

# Local Coverage Determination (LCD): Heavy Metal Testing (L35074)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

## Contractor Information

<b>Contractor Name</b>	<b>Contract Type</b>	<b>Contract Number</b>	<b>Jurisdiction</b>	<b>State(s)</b>
<a href="#">National Government Services, Inc.</a>	MAC - Part A	06101 - MAC A	N/A	Illinois
<a href="#">National Government Services, Inc.</a>	MAC - Part B	06102 - MAC B	N/A	Illinois
<a href="#">National Government Services, Inc.</a>	MAC - Part A	06201 - MAC A	N/A	Minnesota
<a href="#">National Government Services, Inc.</a>	MAC - Part B	06202 - MAC B	N/A	Minnesota
<a href="#">National Government Services, Inc.</a>	MAC - Part A	06301 - MAC A	N/A	Wisconsin
<a href="#">National Government Services, Inc.</a>	MAC - Part B	06302 - MAC B	N/A	Wisconsin
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13101 - MAC A	J - K	Connecticut
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13102 - MAC B	J - K	Connecticut
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13201 - MAC A	J - K	New York - Entire State
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13202 - MAC B	J - K	New York - Downstate
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13282 - MAC B	J - K	New York - Upstate
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13292 - MAC B	J - K	New York - Queens
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14111 - MAC A	J - K	Maine
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14112 - MAC B	J - K	Maine
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14211 - MAC A	J - K	Massachusetts
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14212 - MAC B	J - K	Massachusetts
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14311 - MAC A	J - K	New Hampshire
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14312 - MAC B	J - K	New Hampshire
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14411 - MAC A	J - K	Rhode Island
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14412 - MAC B	J - K	Rhode Island
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14511 - MAC A	J - K	Vermont
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14512 - MAC B	J - K	Vermont

[Back to Top](#)

## LCD Information

### Document Information

LCD ID

Original Effective Date

L35074

For services performed on or after 10/01/2015

Original ICD-9 LCD ID

[L33384](#)

Revision Effective Date

For services performed on or after 01/01/2017

LCD Title

Heavy Metal Testing

Revision Ending Date

N/A

Retirement Date

N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement  
CPT only copyright 2002-2017 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Notice Period Start Date

04/21/2016

Notice Period End Date

06/05/2016

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA." Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

CMS National Coverage Policy Title XVIII of the Social Security Act section 1862 (a)(1)(A). This section allows coverage and payment of those services that are considered to be medically reasonable and necessary.

Title XVIII of the Social Security Act section 1862 (a)(7). This section excludes routine physical examinations and services.

Coverage Guidance

### **Coverage Indications, Limitations, and/or Medical Necessity**

The term heavy metal testing is historically used to describe elements such as lead, arsenic, mercury, cadmium, and chromium. In general, all of the heavy metals in inorganic form cause GI irritation, resulting in nausea, vomiting, abdominal pain and diarrhea. The next most consistent toxicity for the heavy metals as a group, but not for every heavy metal, is renal toxicity. A further generalization is that each member of the heavy metal group tends to cause multi-organ toxicity. Many metals cause cutaneous abnormalities, such as irritant and allergic contact dermatitis, urticaria, keratoses, and premalignant and malignant lesions. Several of the heavy metals produce central and peripheral nervous system toxicity. Other metals cause pulmonary illness.

However, before any testing for heavy metal is ordered, a detailed medical history of the patient must be obtained, including a careful documentation of occupational and avocational exposure to these toxins. A complete physical examination must be done. While classified as heavy metals, this policy does not include iron or lithium since the former is typically tested for anemia issues, discussed in National Coverage Determination 110.10 (Intravenous Iron Therapy), and the latter is typically tested for monitoring of medications. In addition, iron testing is covered under the National Coverage Determination 190.18 (Serum Iron Studies).

1. Aluminum. Serum aluminum testing is payable for beneficiaries who have been on dialysis with evidence suggesting aluminum toxicity, or for beneficiaries with chronic industrial exposure history
2. Antimony. Serum and/or urine antimony testing is payable for beneficiaries with documented treatment in the past with antileishmaniasis agents or with documented chronic antimony industrial exposure history.
3. Arsenic. Serum and whole blood and/or urine arsenic testing is payable for beneficiaries with unexplained peripheral neuropathies, industrial exposure to arsenic, histories of arsenic pesticide exposure, unexplained encephalopathies, unexplained weight loss, chronic glomerulonephritis, bone marrow hypoplasia, or melanosis of skin, unexplained chronic diarrhea, persistent abdominal pain, or nausea and vomiting.
4. Barium. Serum and or/urine barium testing is payable for beneficiaries with pulmonary disease with industrial exposure to barium or unexplained flaccid paralysis.
5. Beryllium. Serum and/or urine beryllium testing is payable for beneficiaries with pulmonary disease with industrial exposure to beryllium.
6. Bismuth. Serum and/or urine bismuth testing is payable for beneficiaries with bismuth lines on their gums, methemoglobinemia, unexplained pathological fractures, or a history of bismuth medicine abuse.
7. Cadmium. Serum and whole blood and/or urine cadmium testing is payable for beneficiaries with an exposure to cadmium with evidence of pulmonary disease or unexplained renal failure.
8. Chromium. Serum chromium testing is payable for beneficiaries with an industrial exposure to chromium with evidence of pulmonary disease.
9. Cobalt. Serum cobalt testing is payable for beneficiaries with an industrial exposure to cobalt with evidence of pulmonary disease
10. Copper. Serum copper testing is payable for beneficiaries with an industrial exposure to copper with evidence of pulmonary disease, for beneficiaries with Wilson's Disease, unexplained cardiomyopathy, unexplained renal failure, polycythemia. unexplained myelodysplastic syndrome or known ingestion of zinc.
11. Lead. Blood (serum and whole) and/or urine lead testing is covered if there is documented industrial exposure to lead, documented avocation exposure to lead, retained bullet fragments at or near joints, a blue gum line, a history of moonshine abuse, unexplained peripheral neuropathies, evidence of lead contaminated drinking water, paint stripping, lead lines on bones on radiographs, or basophilic stippling of red blood cells.
12. Manganese. Serum manganese testing is covered for beneficiaries with documented industrial exposure to manganese.
13. Mercury. Serum, whole blood, and/or urine mercury testing is covered for beneficiaries with documented industrial exposure to mercury, with a blue line in their mouth, those with a history of laxative abuse, with a history of pesticide exposure, mercury spillage with vacuuming of the liquid metal, unexplained renal failure, or a history of skin lightening treatments.
14. Molybdenum. Serum molybdenum testing is covered for beneficiaries with documented industrial exposure to molybdenum.
15. Nickel. Serum and/or urine nickel testing is covered for beneficiaries with documented industrial exposure to nickel, unexplained renal failure, unexplained pulmonary disease.
16. Selenium. Serum and/or urine selenium testing is covered for beneficiaries with documented industrial exposure to selenium or on chronic renal dialysis.
17. Thallium. Serum thallium testing is covered for beneficiaries with documented industrial exposure to thallium and unexplained ataxia.
18. Tin. Serum tin testing is covered for beneficiaries with documented industrial exposure to tin.
19. Titanium. Serum titanium testing is covered for beneficiaries with documented industrial exposure to titanium.
20. Zinc. Serum zinc and/or urine testing is covered for beneficiaries with documented industrial exposure to zinc, on chronic renal dialysis, with malabsorption syndromes, Crohn's disease, unexplained myelodysplastic syndrome or known ingestion of zinc.

21. Testing for the following metals is non-covered: Boron, Phosphorous, Silica, Strontium, Sulfur, Uranium, Vanadium

Documented recent, long-term total parenteral nutrition (TPN) with clinical trace element deficiency evidence is an acceptable medical indication for testing for copper, manganese, and zinc.

[Back to Top](#)

---

## Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

Revenue codes only apply to providers who bill these services to the Part A MAC. Revenue codes do not apply to physicians, other professionals and suppliers who bill these services to the Part B MAC. Please note that not all revenue codes apply to every type of bill code. Providers are encouraged to refer to the FISS revenue code file for allowable bill types. Similarly, not all revenue codes apply to each CPT/HCPCS code. Providers are encouraged to refer to the FISS HCPCS file for allowable revenue codes.

99999 Not Applicable

CPT/HCPCS Codes

**Group 1 Paragraph:** N/A

**Group 1 Codes:**

82108 ALUMINUM

82175 ARSENIC

82300 CADMIUM

82495 CHROMIUM

82525 COPPER

83015 HEAVY METAL (EG, ARSENIC, BARIUM, BERYLLIUM, BISMUTH, ANTIMONY, MERCURY); QUALITATIVE, ANY NUMBER OF ANALYTES

83018 HEAVY METAL (EG, ARSENIC, BARIUM, BERYLLIUM, BISMUTH, ANTIMONY, MERCURY); QUANTITATIVE, EACH, NOT ELSEWHERE SPECIFIED

83655 LEAD

83785 MANGANESE

83825 MERCURY, QUANTITATIVE

83885 NICKEL

84255 SELENIUM

84285 SILICA

84630 ZINC

84999 UNLISTED CHEMISTRY PROCEDURE

## ICD-10 Codes that Support Medical Necessity

**Group 1 Paragraph:** The correct use of an ICD-10-CM code listed below does not assure coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this determination.

### Aluminum

#### Group 1 Codes:

ICD-10 Codes	Description
F06.8	Other specified mental disorders due to known physiological condition
F11.121	Opioid abuse with intoxication delirium
F11.122	Opioid abuse with intoxication with perceptual disturbance
F11.14	Opioid abuse with opioid-induced mood disorder
F11.188	Opioid abuse with other opioid-induced disorder
F11.221	Opioid dependence with intoxication delirium
F11.24	Opioid dependence with opioid-induced mood disorder
F11.288	Opioid dependence with other opioid-induced disorder
F11.921	Opioid use, unspecified with intoxication delirium
F11.929	Opioid use, unspecified with intoxication, unspecified
F11.94	Opioid use, unspecified with opioid-induced mood disorder
F11.988	Opioid use, unspecified with other opioid-induced disorder
F12.121	Cannabis abuse with intoxication delirium
F12.129	Cannabis abuse with intoxication, unspecified
F12.159	Cannabis abuse with psychotic disorder, unspecified
F12.188	Cannabis abuse with other cannabis-induced disorder
F12.221	Cannabis dependence with intoxication delirium
F12.229	Cannabis dependence with intoxication, unspecified
F12.288	Cannabis dependence with other cannabis-induced disorder
F12.921	Cannabis use, unspecified with intoxication delirium
F12.929	Cannabis use, unspecified with intoxication, unspecified
F12.988	Cannabis use, unspecified with other cannabis-induced disorder
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder

<b>ICD-10 Codes</b>	<b>Description</b>
F14.121	Cocaine abuse with intoxication with delirium
F14.129	Cocaine abuse with intoxication, unspecified
F14.14	Cocaine abuse with cocaine-induced mood disorder
F14.188	Cocaine abuse with other cocaine-induced disorder
F14.221	Cocaine dependence with intoxication delirium
F14.229	Cocaine dependence with intoxication, unspecified
F14.24	Cocaine dependence with cocaine-induced mood disorder
F14.288	Cocaine dependence with other cocaine-induced disorder
F14.921	Cocaine use, unspecified with intoxication delirium
F14.929	Cocaine use, unspecified with intoxication, unspecified
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder
F14.988	Cocaine use, unspecified with other cocaine-induced disorder
F15.121	Other stimulant abuse with intoxication delirium
F15.129	Other stimulant abuse with intoxication, unspecified
F15.14	Other stimulant abuse with stimulant-induced mood disorder
F15.188	Other stimulant abuse with other stimulant-induced disorder
F15.221	Other stimulant dependence with intoxication delirium
F15.229	Other stimulant dependence with intoxication, unspecified
F15.24	Other stimulant dependence with stimulant-induced mood disorder
F15.288	Other stimulant dependence with other stimulant-induced disorder
F15.921	Other stimulant use, unspecified with intoxication delirium
F15.929	Other stimulant use, unspecified with intoxication, unspecified
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder
F16.121	Hallucinogen abuse with intoxication with delirium
F16.129	Hallucinogen abuse with intoxication, unspecified
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder
F16.221	Hallucinogen dependence with intoxication with delirium
F16.229	Hallucinogen dependence with intoxication, unspecified
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder
F16.921	Hallucinogen use, unspecified with intoxication with delirium
F16.929	Hallucinogen use, unspecified with intoxication, unspecified
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder
F18.121	Inhalant abuse with intoxication delirium
F18.129	Inhalant abuse with intoxication, unspecified
F18.14	Inhalant abuse with inhalant-induced mood disorder
F18.17	Inhalant abuse with inhalant-induced dementia
F18.188	Inhalant abuse with other inhalant-induced disorder
F18.221	Inhalant dependence with intoxication delirium
F18.229	Inhalant dependence with intoxication, unspecified
F18.24	Inhalant dependence with inhalant-induced mood disorder
F18.27	Inhalant dependence with inhalant-induced dementia
F18.288	Inhalant dependence with other inhalant-induced disorder
F18.921	Inhalant use, unspecified with intoxication with delirium
F18.929	Inhalant use, unspecified with intoxication, unspecified
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia
F18.988	Inhalant use, unspecified with other inhalant-induced disorder
F19.121	Other psychoactive substance abuse with intoxication delirium
F19.129	Other psychoactive substance abuse with intoxication, unspecified
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder

<b>ICD-10 Codes</b>	<b>Description</b>
F19.221	Other psychoactive substance dependence with intoxication delirium
F19.229	Other psychoactive substance dependence with intoxication, unspecified
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder
N18.1	Chronic kidney disease, stage 1
N18.2	Chronic kidney disease, stage 2 (mild)
N18.3	Chronic kidney disease, stage 3 (moderate)
N18.4	Chronic kidney disease, stage 4 (severe)
N18.5	Chronic kidney disease, stage 5
N18.6	End stage renal disease
N18.9	Chronic kidney disease, unspecified
T47.0X4A	Poisoning by histamine H2-receptor blockers, undetermined, initial encounter
T47.0X4D	Poisoning by histamine H2-receptor blockers, undetermined, subsequent encounter
T47.0X4S	Poisoning by histamine H2-receptor blockers, undetermined, sequela
T47.1X4A	Poisoning by other antacids and anti-gastric-secretion drugs, undetermined, initial encounter
T47.1X4D	Poisoning by other antacids and anti-gastric-secretion drugs, undetermined, subsequent encounter
T47.1X4S	Poisoning by other antacids and anti-gastric-secretion drugs, undetermined, sequela
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela
T82.898A	Other specified complication of vascular prosthetic devices, implants and grafts, initial encounter
T82.898D	Other specified complication of vascular prosthetic devices, implants and grafts, subsequent encounter
T82.898S	Other specified complication of vascular prosthetic devices, implants and grafts, sequela

**Group 2 Paragraph: Antimony**

**Group 2 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
B55.9	Leishmaniasis, unspecified
T56.891A	Toxic effect of other metals, accidental (unintentional), initial encounter
T56.891D	Toxic effect of other metals, accidental (unintentional), subsequent encounter
T56.891S	Toxic effect of other metals, accidental (unintentional), sequela

**Group 3 Paragraph: Arsenic**

**Group 3 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
D61.1	Drug-induced aplastic anemia
D61.2	Aplastic anemia due to other external agents
D61.3	Idiopathic aplastic anemia
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes
G60.0	Hereditary motor and sensory neuropathy
G60.2	Neuropathy in association with hereditary ataxia

<b>ICD-10 Codes</b>	<b>Description</b>
G60.9	Hereditary and idiopathic neuropathy, unspecified
G61.1	Serum neuropathy
G62.2	Polyneuropathy due to other toxic agents
G62.82	Radiation-induced polyneuropathy
G93.40	Encephalopathy, unspecified
G93.41	Metabolic encephalopathy
G93.49	Other encephalopathy
I67.83	Posterior reversible encephalopathy syndrome
K52.21	Food protein-induced enterocolitis syndrome
K52.22	Food protein-induced enteropathy
K52.29	Other allergic and dietetic gastroenteritis and colitis
K52.89	Other specified noninfective gastroenteritis and colitis
K63.4	Enteroptosis
K63.89	Other specified diseases of intestine
K92.89	Other specified diseases of the digestive system
L23.1	Allergic contact dermatitis due to adhesives
L23.5	Allergic contact dermatitis due to other chemical products
L24.5	Irritant contact dermatitis due to other chemical products
L25.3	Unspecified contact dermatitis due to other chemical products
N03.9	Chronic nephritic syndrome with unspecified morphologic changes
R11.2	Nausea with vomiting, unspecified
R19.7	Diarrhea, unspecified
R63.4	Abnormal weight loss
T57.0X4A	Toxic effect of arsenic and its compounds, undetermined, initial encounter
T57.0X4D	Toxic effect of arsenic and its compounds, undetermined, subsequent encounter
T57.0X4S	Toxic effect of arsenic and its compounds, undetermined, sequela

**Group 4 Paragraph:** Barium

**Group 4 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
J98.4	Other disorders of lung
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 5 Paragraph:** Beryllium

**Group 5 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
J98.4	Other disorders of lung
T56.7X4A	Toxic effect of beryllium and its compounds, undetermined, initial encounter
T56.7X4D	Toxic effect of beryllium and its compounds, undetermined, subsequent encounter
T56.7X4S	Toxic effect of beryllium and its compounds, undetermined, sequela

**Group 6 Paragraph:** Bismuth

**Group 6 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
D74.8	Other methemoglobinemias
D74.9	Methemoglobinemia, unspecified
K05.5	Other periodontal diseases
M84.40XA	Pathological fracture, unspecified site, initial encounter for fracture
M84.40XD	Pathological fracture, unspecified site, subsequent encounter for fracture with routine healing
M84.40XS	Pathological fracture, unspecified site, sequela
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter



<b>ICD-10 Codes</b>	<b>Description</b>
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 7 Paragraph: Cadmium**

**Group 7 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
J98.4	Other disorders of lung
N19	Unspecified kidney failure
T56.3X4A	Toxic effect of cadmium and its compounds, undetermined, initial encounter
T56.3X4D	Toxic effect of cadmium and its compounds, undetermined, subsequent encounter
T56.3X4S	Toxic effect of cadmium and its compounds, undetermined, sequela

**Group 8 Paragraph: Chromium**

**Group 8 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
J98.4	Other disorders of lung
T56.2X4A	Toxic effect of chromium and its compounds, undetermined, initial encounter
T56.2X4D	Toxic effect of chromium and its compounds, undetermined, subsequent encounter
T56.2X4S	Toxic effect of chromium and its compounds, undetermined, sequela

**Group 9 Paragraph: Cobalt**

**Group 9 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
J98.4	Other disorders of lung
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 10 Paragraph: Copper**

**Group 10 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.20	Refractory anemia with excess of blasts, unspecified
D46.21	Refractory anemia with excess of blasts 1
D46.22	Refractory anemia with excess of blasts 2
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.4	Refractory anemia, unspecified
D46.Z	Other myelodysplastic syndromes
D46.9	Myelodysplastic syndrome, unspecified
E83.00	Disorder of copper metabolism, unspecified
E83.09	Other disorders of copper metabolism
I42.9	Cardiomyopathy, unspecified
J98.4	Other disorders of lung
K73.0	Chronic persistent hepatitis, not elsewhere classified
K73.9	Chronic hepatitis, unspecified
K74.60	Unspecified cirrhosis of liver
K74.69	Other cirrhosis of liver
K76.9	Liver disease, unspecified
N19	Unspecified kidney failure
Q89.8	Other specified congenital malformations

<b>ICD-10 Codes</b>	<b>Description</b>
R63.3	Feeding difficulties
R74.8	Abnormal levels of other serum enzymes
R74.9	Abnormal serum enzyme level, unspecified
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 11 Paragraph: Lead**

**Group 11 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
G58.8	Other specified mononeuropathies
G58.9	Mononeuropathy, unspecified
G60.0	Hereditary motor and sensory neuropathy
G60.1	Refsum's disease
G60.2	Neuropathy in association with hereditary ataxia
G60.3	Idiopathic progressive neuropathy
G60.8	Other hereditary and idiopathic neuropathies
G60.9	Hereditary and idiopathic neuropathy, unspecified
G93.40	Encephalopathy, unspecified
G93.41	Metabolic encephalopathy
G93.49	Other encephalopathy
R71.0	Precipitous drop in hematocrit
R71.8	Other abnormality of red blood cells
R93.6	Abnormal findings on diagnostic imaging of limbs
R93.7	Abnormal findings on diagnostic imaging of other parts of musculoskeletal system
T56.0X4A	Toxic effect of lead and its compounds, undetermined, initial encounter
T56.0X4D	Toxic effect of lead and its compounds, undetermined, subsequent encounter
T56.0X4S	Toxic effect of lead and its compounds, undetermined, sequela

**Group 12 Paragraph: Manganese**

**Group 12 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
G25.70	Drug induced movement disorder, unspecified
G25.71	Drug induced akathisia
G25.79	Other drug induced movement disorders
G25.89	Other specified extrapyramidal and movement disorders
G25.9	Extrapyramidal and movement disorder, unspecified
G26	Extrapyramidal and movement disorders in diseases classified elsewhere
R63.3	Feeding difficulties
T57.2X4A	Toxic effect of manganese and its compounds, undetermined, initial encounter
T57.2X4D	Toxic effect of manganese and its compounds, undetermined, subsequent encounter
T57.2X4S	Toxic effect of manganese and its compounds, undetermined, sequela

**Group 13 Paragraph: Mercury**

**Group 13 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
G11.1	Early-onset cerebellar ataxia
G25.70	Drug induced movement disorder, unspecified
G25.71	Drug induced akathisia
G25.79	Other drug induced movement disorders
G25.89	Other specified extrapyramidal and movement disorders
G25.9	Extrapyramidal and movement disorder, unspecified
G26	Extrapyramidal and movement disorders in diseases classified elsewhere

<b>ICD-10 Codes</b>	<b>Description</b>
G32.81	Cerebellar ataxia in diseases classified elsewhere
I69.093	Ataxia following nontraumatic subarachnoid hemorrhage
I69.193	Ataxia following nontraumatic intracerebral hemorrhage
I69.293	Ataxia following other nontraumatic intracranial hemorrhage
I69.393	Ataxia following cerebral infarction
I69.893	Ataxia following other cerebrovascular disease
I69.993	Ataxia following unspecified cerebrovascular disease
N19	Unspecified kidney failure
R27.0	Ataxia, unspecified
R27.8	Other lack of coordination
R27.9	Unspecified lack of coordination
T37.8X1A	Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), initial encounter
T37.8X1D	Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), subsequent encounter
T37.8X1S	Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), sequela
T47.4X4A	Poisoning by other laxatives, undetermined, initial encounter
T47.4X4D	Poisoning by other laxatives, undetermined, subsequent encounter
T47.4X4S	Poisoning by other laxatives, undetermined, sequela
T49.8X4A	Poisoning by other topical agents, undetermined, initial encounter
T49.8X4D	Poisoning by other topical agents, undetermined, subsequent encounter
T49.8X4S	Poisoning by other topical agents, undetermined, sequela
T56.1X4A	Toxic effect of mercury and its compounds, undetermined, initial encounter
T56.1X4D	Toxic effect of mercury and its compounds, undetermined, subsequent encounter
T56.1X4S	Toxic effect of mercury and its compounds, undetermined, sequela

**Group 14 Paragraph: Molybdenum**

**Group 14 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 15 Paragraph: Nickel**

**Group 15 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
J98.4	Other disorders of lung
N19	Unspecified kidney failure
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 16 Paragraph: Selenium**

**Group 16 Codes:**

<b>ICD-10 Codes</b>	<b>Description</b>
N19	Unspecified kidney failure
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 17 Paragraph: Thallium**

**Group 17 Codes:**

ICD-10 Codes	Description
G62.2	Polyneuropathy due to other toxic agents
R27.0	Ataxia, unspecified
R27.8	Other lack of coordination
R27.9	Unspecified lack of coordination
T56.814A	Toxic effect of thallium, undetermined, initial encounter
T56.814D	Toxic effect of thallium, undetermined, subsequent encounter
T56.814S	Toxic effect of thallium, undetermined, sequela

**Group 18 Paragraph: Tin****Group 18 Codes:**

ICD-10 Codes	Description
T56.6X4A	Toxic effect of tin and its compounds, undetermined, initial encounter
T56.6X4D	Toxic effect of tin and its compounds, undetermined, subsequent encounter
T56.6X4S	Toxic effect of tin and its compounds, undetermined, sequela

**Group 19 Paragraph: Titanium****Group 19 Codes:**

ICD-10 Codes	Description
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela

**Group 20 Paragraph: Zinc****Group 20 Codes:**

ICD-10 Codes	Description
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.20	Refractory anemia with excess of blasts, unspecified
D46.21	Refractory anemia with excess of blasts 1
D46.22	Refractory anemia with excess of blasts 2
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.4	Refractory anemia, unspecified
D46.Z	Other myelodysplastic syndromes
D46.9	Myelodysplastic syndrome, unspecified
K50.90	Crohn's disease, unspecified, without complications
K50.918	Crohn's disease, unspecified, with other complication
K50.919	Crohn's disease, unspecified, with unspecified complications
K90.9	Intestinal malabsorption, unspecified
N19	Unspecified kidney failure
R63.3	Feeding difficulties
T56.5X4A	Toxic effect of zinc and its compounds, undetermined, initial encounter
T56.5X4D	Toxic effect of zinc and its compounds, undetermined, subsequent encounter
T56.5X4S	Toxic effect of zinc and its compounds, undetermined, sequela

ICD-10 Codes that DO NOT Support Medical Necessity

**Group 1 Paragraph:** ICD10 codes not listed above

**Group 1 Codes:****ICD-10 Codes Description**

ICD-10 Codes	Description
XX000	Not Applicable

ICD-10 Additional Information

[Back to Top](#)

## General Information

Associated Information  
N/A

Sources of Information and Basis for Decision  
National Library of Medicine: IGM Full Record Screen  
Carrier Advisory Committee

[Back to Top](#)

## Revision History Information

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
01/01/2017	R4	Based on the CPT/HCPCS annual update, the descriptions for the following codes in Group 1 have been changed: 83015 and 80318. Revised the following language in the Coverage Indications, Limitations section from " While classified as heavy metals, this policy does not include iron or lithium since the former is typically tested for anemia issues, and the latter is typically tested for monitoring of medications." to " While classified as heavy metals, this policy does not include iron or lithium since the former is typically tested for anemia issues, discussed in National Coverage Determination 110.10 (Intravenous Iron Therapy), and the latter is typically tested for monitoring of medications." No change in coverage.	<ul style="list-style-type: none"> <li>Provider Education/Guidance</li> <li>Revisions Due To CPT/HCPCS Code Changes</li> </ul>
10/01/2016	R3	Added ICD-10-CM Diagnosis codes K52.21, K52.22, and K52.29 to the ICD-10 Codes that Support Medical Necessity section, Group 3, due to the annual ICD-10-CM update.	<ul style="list-style-type: none"> <li>Revisions Due To ICD-10-CM Code Changes</li> </ul>
06/06/2016	R2	DL35074 was released to a final LCD L35074, effective for services rendered on or after June 6, 2016. No official comments were received. The policy will be in the notice period from April 21, 2016 though June 5, 2016.	<ul style="list-style-type: none"> <li>Provider Education/Guidance</li> <li>Creation of Uniform LCDs With Other MAC Jurisdiction</li> </ul>
10/01/2015	R1	Added 7th digit to ICD-10-CM diagnosis codes to diagnosis code groups where appropriate.	<ul style="list-style-type: none"> <li>Provider Education/Guidance</li> </ul>

[Back to Top](#)

## Associated Documents

Attachments N/A

Related Local Coverage Documents N/A

Related National Coverage Documents N/A

Public Version(s) Updated on 12/19/2016 with effective dates 01/01/2017 - N/A [Updated on 09/22/2016 with](#)

## **Keywords**

N/A Read the [LCD Disclaimer](#) [Back to Top](#)